The Cost-Effectiveness of Continuous Erythropoiesis Receptor Activator Once Monthly versus Epoetin Thrice Weekly for Anaemia Management in Chronic Haemodialysis Patients

Table 2

Anaemia management during the study.

Parameters	EpoB phase	CERA phase
	75	75
Hemoglobin g/dL	11.25 ± 0.73	11.42 ± 0.63	0.08
Transferrin saturation %	28.4	29.2	0.35
Ferritin ng/mL	288.5	299.3	0.2
IV iron %	87.5	89.1	0.23
IV iron dosage mg/month	110,5 ± 11.2	116,3 ± 13.3	0.11
ESA dose	6104 ± 3178 ui	106.4 ± 50.1 g
CSR   %	49 (65.3)	53 (70.7)	0.008
Hb > 12 g/dL; (%)	12 (16)	15 (20)	0.001
Hb < 10.5 g/dL; (%)	14 (18.7)	7 (9.3)	0.001

CSR: clinical success rate Hb within the range 10.5–12 g/dL.
ESA: erythropoietin stimulating agent.
Hb: haemoglobin.
EpoB: epoetin beta.
CERA: continuous erythropoietin receptor activator.